throbber
Is
`
`My ANTIHISTAMINE
`
`SAFE?
`
`by Laurel Ashworth, PharmD
`
`I
`,~.
`
`·f,l, .
`I
`
`,;
`
`(FDA) has
`The Food and Drug Administration
`announced its intention to withdraw the approval of ter­
`fenadine (Seldane), terfenadine,with pseudoephedrine
`(Seldane D), and generic versiotls of terfenadine.' Before
`granting approval for the marketing of fexofenadine
`(Allegra), terfenadine's active metabolite, the FDA deter­
`mined terfenadine's benefits outweigh its risks, despite its
`known potential for serious cardiac effects.
`
`Although its therapeutic benefits are equivalent to those
`of terfenadine, fexofenadine appears to be free of the poten­
`tial for adverse cardiac effects. 2 Patients who take terfena­
`dine or h-ave taken it in the past have heard or read about
`the FDA's intent to withdraw terfenadine from/the market
`and are understandably concerned.
`
`To varying degrees, antihistamines possess sedative, anti­
`histaminic, anticholinergic, and/or antiemetic effects:'
`Diphenhydramine (Benadryl), for example, has pronounced
`sedative and moderate antihistaminic effects. Thus it is
`commonly used as a sleeping aid or as treatment for allergic
`and nonallergic pruritic symptoms. Brompheniramine
`(Dimetane) and chlorpheniramine (Chlor-Trimetin) have
`strong antihistaminic activity, minimal sedation, and can
`provide temporary relief of runny nose and sneezing as a
`result of the common cold. Proniethazine (Phenergan)
`has potent antiemetic properties. For all their benefits, con­
`ven\ional antihistamines have one overwhelming drawback:
`many patients cannot take them and function normally in
`the work-a-day world because antihistamines make them
`too sleepy.
`
`In 1985, terfenadine was introduced to the American mar­
`ket to relieve the symptoms of allergic rhinitis without
`causing drowsiness. Astemizole (Hismanal) followed in
`1988, loratadine (Claritin) in 1993, and fexofenadine in
`July 1996. The indications for these four products appear
`in Table 1. Despite the fact their cost is many-fold higher
`than older antihistamines, these new agents enjoy
`Widespread use. They are relatively long-acting and effec­
`tive, have minimal unpleasant (anticholinergic) effects,
`and cause little or no sedation: In the common vernacular,
`
`Table I
`Comparison of FDA-approved Indications
`for Nonsedating Antihistamines8
`
`,9.,1,'2
`
`INDICATION
`Seasonal allergic
`Idiopathic chronic
`rhinitis
`urticaria '
`X
`X
`X
`X­
`X
`
`X
`
`Astemizole
`Fexofenadine
`Loratadine
`Terfenadine
`
`JUNE 1997, VOL. 2 NO.3
`
`HOME CARE PROVIDER 117
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1018 - Page 1
`
`

`
`Table 2
`Dosing Guidelines for Nonsedating Antihistamines8
`
`,9,11,11
`
`WHEN PAT1ENTS ASK
`
`._-,_._"_._-,----_.~.__.,_._---­
`Parameter
`Normal dose:
`people 212 years
`
`Fexofenadine
`-_._,.-.-"-,_._---_._,._--_._~,_._ •. _.
`60 mg BID
`
`- - -­
`
`Loratadine
`-- ­ --­ --­
`- ­ - -­
`10 mg once daily
`
`-
`
`- -
`
`-
`
`Terfenadine
`60 mg BID
`
`Astemizole
`-,-,._---~--------,-_._--,--,_.__.
`10 mg once daily
`22 ho~rs after meals
`with no additional
`
`_____________________i2.2.cl.~_!_h2.u..r
`Dosage change
`Avoid drug
`_in..l1.e..E.a,1:i<:._cJy_.~.flJ..~~~~n___
`.
`Use only with caution
`Dosage change
`in renal dysfunction
`
`_
`
`_
`
`_ .__._._---------.-._-­
`60 mg once daily
`
`10 mg every other day
`._._---_.__._._- ~._-.-_---_.- -_. --_ .
`10 mg every other
`day if GFR < 30 mLlmin
`
`Contraindicated
`
`.-._-.---- -­ ---_.-. ._--.--­
`
`..
`
`I
`
`I
`
`,~ ,
`"j,
`!
`
`(
`
`~'~,-
`
`I
`
`I
`I
`
`II
`
`
`.~
`..c,.
`
`they are known as the "nonsedating" antihistamines. During
`1996, 12,834,000 prescriptions were fil1ed for loratadine,
`ranking it number 16 in the top 200 m«st commonly
`dispensed drugs in America. s Seldane ranked number 86
`with 4,938,000 prescriptions filled in 1996 5
`
`TERFENADINE TROUBLES
`:Several years after terfenadine was marketed, case reports
`of serious cardiac arrhythmias (torsades de pointes) a~d
`deaths associated with terfenadine use began to appear in
`the medical literature 6,' In time, it became clear that car­
`diotoxicity was promoted by elevated terfenadine levels.
`The concomitant use of terfenadine with certain macrolide
`antibiotics and imidazole antifungals delayed the bio­
`transfonnation of terfenadine to its active metabolite, allow­
`ing toxic levels of the parent drug to accumulate, The
`ingestion of large quantities of terfenadine in excess of the
`dosage prescribed and/or the presence of significant hep­
`atic impairment likewise contributed to terfenadine-asso­
`ciated cardiotoxkity.' The dosage guidelines recommended
`by the manufacturers appear in Table 2.
`
`Subsequent to these case reports, the FDA required the
`manufacturer to issue a "Dear Doctor Letter" in August
`1990. In July 1992, terfenadine manufacturers were required
`to add a "black-box warning" to their package insert: The
`new product labeling alerted users to a possible interaction
`. if terfenadine were taken simultaneously with erythromycin,
`tr~leandomycin, ketoconazole, or itraconazole. The warn­
`ing since has been expanded to include c1arithromycin, a
`newer imtibiotic of the erythromycin (macrolide) family.'
`Similar serious cardiovascular adverse events have occurred
`with the concomitant administration of a~temizole and
`ketoconazole tablets, itraconazole, erythromycin, or qui­
`nine. Today, the black-box warning in the astemizole
`package insert bears a striking resemblance to the terfena­
`dine insert,.'
`
`Although patient counseling and prominent warnings have
`reduced the incidence of terfenadine-induced cardiotoxicity
`
`secondary to drug-drug interactions, the FDA believes the
`incidence of these interactions is still unacceptably high
`and therefore is taking steps to remove terfenadine-contain­
`ing products from the market. The parent compounds,
`not the metabolites, for both terfenadine and astemizole
`are cardiotoxic,.',o Thus far, loratadine and fexofenadine
`have not bee!13ssociated with adverse cardiac events.",12
`
`,
`
`'
`To compr;ehend why one member of a closely related ther­
`apeutic dass (the nonsedating antihistamines) can provoke
`cardiotoxicity while another does not, users need to under­
`stand the enzymes that metabolize these drugs. The term
`cytochrome P450 refers to a group of enzymes located on
`the endoplasmic reticulum. Although present in all tissues,
`the highest concentrations are Found in the liver and smal1
`intestine, with much smaller quantities in the kidneys,
`lungs, and brain."14 The primary biologic functions of these
`enzymes appear to be twofold: metabolism of endogenous
`compounds and detoxification of exogenous compounds. IS
`
`Cyp CONCERNS
`In the literature, the abbreviation CYP is used to denote
`cytochrome P450, As of 1993, 12 families common to al1
`mammals have been identified. In humans, enzymes of
`the CYP1, CYP2, and CYP3 families are responsible for
`most drug metabolism and account for at least 70% of the
`total CYP content in human liver samples." The CYP iso­
`forms are very specific with regard to their substrates,
`inhibitors, or inducers. For example, isoform CYPtA2
`metabolizes theophylline; CYP2D6 is important in the bio­
`transfonmation of antidepressants and antipsychotics;
`CYP2C9 metabolizes phenytoin and the nonsteroidal anti­
`inflammatory drugs. 10
`
`Terfemidine undergoes oxidation by CYP3A4 to desalkyl
`and hydroxy metabolites. The hydroxy metabolite, in turn,
`is converted to a carboxylic acid derivative (fexofenadine),
`whose plasma concentration~ exceed those of the parent·'
`compound by;::: 1oO-fold. 16 In the absence of liver disease
`or drug interactions, terfenadine is barely detectable in
`
`118 HOME CARE PROVIDER
`
`JUNE 1997, VOL 2 NO.3
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1018 - Page 2
`
`

`
`WHEN PATIENTS ASK
`
`Table 3
`Pharmacokinetic Parameters of Nonsedating Antihistamines3
`,B,9,11,12
`
`Parameter
`Onset of activity
`
`Half-life
`
`Astemizole
`*
`20 to 60 hours
`
`Fexofenadine
`I hour
`~ 14 hours
`
`Loratadine
`I hour
`B hours-parent
`28 hours-metabolite
`
`Terfenadine
`2 to 4 hours
`16 to 23 hours
`
`Protein binding
`
`97%
`
`60 to 70%
`
`97 to 99%
`
`------)'--=-~*:*_----­
`97%
`
`* Without a loading dose, t ll2 may be up to I week, Biphasic elimination: 20 hours for distribution phase; 7 to II days for elimination phase
`** Hydroxylated metabolites, primarily desmethylastemizole
`*** Descarboethoxyloratadine is active and has a t ll2 of 17 to 24 hours
`**** The active metabolite is fexofenadine
`
`plasma except when concomitant
`medications inhibit its metabolism,17,1B
`Fexofenadine, rather than terfenadine,
`is responsible for the antihistaminic
`activity and apparently has no effect
`on the heart, On the other hand,
`terfenadine has no antihistaminic activ­
`ity but inhibits potassium slow chan­
`nels in cardiac tissue in a concentration­
`dependent fashion_ This inhibition
`can prolong the QTc interval of the
`electrocardiogram and increases the
`risk of potentially fatal arrhythmias.'9
`21 The situation is similar for astemi­
`zole in that substantial first-pass
`metabolism occurs and active metaqo­
`lites are formed, 10 Table 3 summari~es
`selected pharmacokinetic 'parameters
`of the nonsedating antihistamines.
`
`AN IMPROVED
`
`
`inhibit the metabolism of loratadine
`and its metabolite descarboethoxy­
`loratadine (DCl). Fortunately
`these interactions appear to be of
`little clinical significance because
`neither electrocardiographic
`abnormalities nor other adverse car­
`diac events have been observed as
`a result of elevated plasma concen­
`trations of DCL. 2 loratadine's
`apparent lack of cardiotoxic effects
`.may be attributable in part to the
`fact that it does not block the potas­
`sium channel involved in repolar­
`ization of cardiac cel1s, Prolonged
`QTc interval has not been detect­
`ed clinically with fexofenadine. 2
`
`•
`
`,
`
`Terfenadine, astemizole, and lorata­
`dine are metabolized by CYP3A4,22
`The imidazole antifungal agents keto­
`conazole and itraconazole are potent
`and relatively specific inhibitors of
`CYP3A activity, Of the two,however,
`only ketoconazole has been associated with terfena­
`dine-induced ventricular arrhythmias, 18,23 Although itra­
`conazole impairs terfenadine metabolism to a lesser
`degree than ketoconazole, available evidence suggests
`itraconazole should not be administered with terfenadine
`or astemizole because of its potential to inhibit CYP3A to
`the same degree as ketoconazole, At usual therapeutic
`doses, fluconazole does not detectably impair terfenadine
`c1'earance,B The new antifungal agent terbinafine does not
`appear toinhibit CYP to a clinically significant extent. 2
`
`Studies show that ketoconazole and erythromycin can
`
`I
`~I
`l
`
`j
`~\,
`
`I
`I
`i
`
`I
`I
`l
`I
`.!
`~
`I
`I
`'(
`"
`(
`
`1
`(
`(
`.!
`I­
`
`The macrolide antibiotics are also
`inhibitors of CYP3A. Azithromycin
`does not appear to inhibit terfena­
`dine metabolism to a significant
`extent, in contrast to erythromycin
`and clarithromycin. 2 Grapefruit
`juice, which contains flavonoids
`that can inhibit CYP3A4, alsb can
`increase plasma levels of unmetabolized terfenadine," An
`improved understanding of the way CYP enzymes metab­
`olize drugs has the potential to improve drug therapy
`by al10wing clinicians to better predict whic;h therapies
`are likely to interact adversely with one another and
`take steps to avoid such situations.
`
`LEARNING FROM MISFORTUNE
`Life teaches by negative as well as positive examples,
`Valuable lessons were learned from careful analysis of the
`unfortunate astemizole- and terfenadine-associated cases
`of torsades de pointes and the codependency that non-
`
`JUNE 1997, VOL 2 NO.3
`
`HOME CARE PROVIDER 119
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1018 - Page 3
`
`

`
`,I
`:t
`
`WHEN PATIENTS ASK
`
`cytochrome P450 31>.(41 in ~-deaIKylation and Chydroxylation
`Drug Metab Dispos 1992;21 :403-9
`17. Honig PK, Woosley Rl, Zamoni K, Conner D, Cantilena l
`Changes in the pharmacokinetics ond electrocardiographic
`pharmacodynamb of terfenadine with concomitant administrat'on
`of erythromycin. Clin Pharmacol Ther 1992;52:231-8.
`18. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC,
`Cantilena lR. Terferadine-ketoconazole interaction: pharmacoki­
`netic and electrocardiographic consequences. JAMA
`1993;2691513-8.
`19. Woosley Rl, Chen Y, Freiman JP, G:llis RA Mechanism of the
`cardiotoxic actions of terfenadine. JAMA 1993 ;269: 1532-6.
`20. Monahan BP, Ferguson Cl, Kileavy ES, Lloyd BK, Troy J,
`Cantilena lR. Torsades de pO·lrtes occurring in association with
`terfenadine use. JAMA 1990;264:2788-90.
`21. Woosley Rl, Chen Y, Pinney SP. Terfenadine and cardiac death.
`j Allergy Clin Immunol 1993;91 :262.
`22. Ketter TA, Flockhart DA, Past RM. The emerging role of
`cytochrome P450 3A in psychopharmocology. J Clin
`Psychopharmacol 1995; 15:387-98.
`23. Von Moltke ll, Greenblatt DJ, Duan SX, HarmatzJS, Wright CE,
`Shaderpj Inhibition of terfenadine metabolism in vitro byazole
`antifungal agents and by selective serotonin reuplake inhibitor
`anti,J~pressants: relatior to pharmacokinetic interactions in vivo. J
`Clrn Psychophacmacol 1996: 16: 104-12.
`24. Haria M, Fitton A, Peters DH
`loratadine: a reappraisal of its
`" pharmacological properties ond therapeutiC uses in allergiC disor­
`ders. Drugs 1994;48:617-37.
`.25. Honig P, WOrtham D, lazarev A, Cantilena lR Grapefruit iuice
`alters the systemic bioavailability and cardiac repolarizalion of
`terfenadine in poor metabolizers ofterfenadine. JClin Pharmacol
`1996;36:345-51.
`
`sedating antihistamines and certain antibiotics/antifungals
`have for specific isoenzymes. From these cases and the
`research they generated came an appreciation of the mul­
`tifaceted, highly specific nature of the CYP family of
`enzymes. In recent years, we have become aware that a
`patient's ethnicity, gender, and inherent CYP idiosyncracies
`influence how he or she metabolizes drugs. Much work
`remains to be done, but at least the process has begun that
`will lead to a better understanding of why two similarly
`matched patients can respond in entirely different ways
`to a given dose of the same medication. We have so much
`yet to learn about the clinical nuances of cytochrome P450.
`
`REFERENCES
`1. Cruzan SM. FDA talk paper [cited 13 january 1997]. Available at
`http://w'ivw. fda. gov/bbs/topics/ANSWERS/ANS00780. hlml
`2. Fexofenadine. Med lett DrugTher 1996;38(9861:95-6
`! 3. Hebel SK, publisher. Focts and comparisons. St. louis (MOl: Facts
`·and Comparisons; 1993: p. 188
`4. Masheter He. Terfenadme: the first nonsedating antihistamine.
`Clin Rev Allergy Immunol 1993: 11 :5-34.
`5
`The top 200 drugs American Druggist 1997;214i2j:30-7.
`6. Mathews DR, McNutt B, Okerholm R, Flicker M, McBride G.
`Torsades de poinfes occurring in association with terfenadine use.
`JAMA 1991 ;266:2375-6.
`7. Crane jK, Shih H-T. Syncope ond cardiac arrhythmia due to an
`interaction between itraconazole and terfenadine. Am J Med
`1993;95:456.
`8. Product information. Seldane brand of lerfenadine. Hoechst
`Marion Roussel, Kansas City [MOl; 1995.
`9. Product information Hismanal brand of astemizole. Janssen
`Pharmaceutica, Titusville (t'-UI; 1993.
`10. Cupp MJ, Tracy TS. Role of the cytochrome P450 3A subfamily
`in drug interactions. US Pharmacist 1997;22:HS9-21.
`11. Product information. Claritin branq of lorotadine. Schering Corp.,
`Kenilworth INJ); September 1995.
`12 Product informotion. Allegra brand of fexofenadine Hoechst
`Marion Rbussel, Kansas City (MOl; August 1996.
`13. Slaughter RI, Edwards Dj. Recent advances: the cytochrome
`P450 enzymes. Ann Pharmocother 1995;29:619-24.
`14. Murray M, Reidy GF. SelectiVity in the inhibition of mammalian
`cytochromes P450 by chemical agents. Pharmocol Rev
`1990;42:85-101.
`15. Krishna D, Klotz U. Extrahepatic metabolism of drugs in humons.
`Clin Pharmacokinet 1994;26: 144-60.
`'
`': 16. Yun C, Okerholm RA, Guengerich FP. OXidation of the antihis­
`taminic drug terfenadine in the human liver microsomes: role of
`
`!
`
`C
`I

`I
`c
`.~
`
`,
`
`
`"
`(
`
`C
`E
`~
`.s:.
`I­
`
`120 HOME CARE PROVIDER
`
`JUNE 1997, VOL. 2 1\0. 3
`
`J.
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1018 - Page 4

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket